Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Gastroenterology · Anal Fistula in Crohn's Disease

Crohn's Disease: A Specialized Path to Healing

At a Glance

Treating an anal fistula in Crohn's disease requires a combined medical and surgical approach. A surgeon drains the infection, often using a seton, while a gastroenterologist uses anti-TNF biologics to reduce inflammation. Stem cell therapies now offer hope for hard-to-treat fistulas.

For patients with Crohn’s disease, an anal fistula is not just a localized issue; it is a manifestation of an underlying immune system disorder [1][2]. Crohn’s-related fistulas are often more “complex,” meaning they may have multiple tunnels, branches, or active infection (abscesses) [3][4].

Because of this complexity, the best chance for healing comes from a multidisciplinary approach—where your gastroenterologist and colorectal surgeon work together to treat both the infection and the inflammation simultaneously [5][6].

The Medical-Surgical Synergy

In Crohn’s disease, surgery alone rarely cures a fistula because the underlying inflammation remains. Conversely, medication alone often struggles to heal a fistula if there is an undrained pocket of infection [7][8].

  1. Surgical Drainage: A surgeon typically performs an Examination Under Anesthesia (EUA) to drain any abscesses and place a seton (a thin, soft loop) to keep the tract open and draining [5][8].
  2. Medical Control: Once drainage is established, your gastroenterologist starts or optimizes “biologic” medications to reduce the internal inflammation [9][10].

Anti-TNF Therapy: The First Line

The “gold standard” medical treatment for Crohn’s fistulas involves anti-TNF agents, such as Infliximab or Adalimumab [10][11].

  • Inducing Remission: These drugs work by blocking a protein in your immune system (TNF-alpha) that causes inflammation [12].
  • The Importance of Dosing: Research shows that achieving “therapeutic levels” of these drugs in your bloodstream is critical. Patients with higher levels of the medication in their system often have much better rates of fistula closure [13][14].
  • Combined Success: Using anti-TNF therapy alongside surgical seton placement is significantly more effective than using medication alone [7][9].

Stem Cell Therapy: A New Frontier

For patients whose fistulas do not respond to standard biologics, a newer option called Mesenchymal Stem Cell (MSC) therapy (specifically darvadstrocel) has emerged [15][16].

  • How it Works: These are specialized cells (often derived from healthy donor fat tissue) that are injected directly into the walls of the fistula tract [15][16].
  • The Goal: These cells help calm the local immune response and promote tissue repair without the need to cut the sphincter muscles [17][18].
  • The Evidence: Clinical trials, such as the ADMIRE-CD study, have shown that stem cell therapy can significantly improve the chances of complete fistula closure in patients who have not found success with other treatments [15][19].

Looking Toward the Future

While Crohn’s-related fistulas are challenging, the treatment landscape is rapidly evolving. The focus has shifted from just “managing” symptoms to achieving radiological healing—where an MRI shows that the tract has truly closed [20][21]. By combining the latest surgical techniques with optimized biologic and regenerative therapies, many patients can achieve long-term remission and a significantly better quality of life [22][23].

Common questions in this guide

Why do anal fistulas happen in Crohn's disease?
In Crohn's disease, an anal fistula is often a manifestation of underlying immune system inflammation. This chronic inflammation can cause abnormal tunnels or branches to form, connecting the bowel to the skin around the anus.
Why do I need both a gastroenterologist and a surgeon to treat my fistula?
Healing a Crohn's-related fistula requires treating both the local infection and the internal inflammation simultaneously. A surgeon drains the infection and may place a seton, while a gastroenterologist prescribes biologic medications to heal the tissue from the inside out.
What is the purpose of a seton in treating a fistula?
A seton is a thin, soft loop placed by a surgeon through the fistula tract. It keeps the tunnel open so any infection can drain completely, preventing new abscesses from forming while medications work to reduce inflammation.
Can stem cell therapy help heal Crohn's fistulas?
Yes, mesenchymal stem cell therapy is a newer treatment option for fistulas that do not respond to standard biologic medications. Specialized cells are injected directly into the fistula walls to calm the local immune response and promote tissue repair.
How do I know if my fistula treatment is working?
Successful treatment usually leads to reduced drainage and closure of the external openings on the skin. Doctors increasingly rely on MRI scans to confirm radiological healing, ensuring that the internal tract has completely closed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are my fistulas considered simple or complex, and how does that change our treatment approach?
  2. 2.Is my Crohn's disease currently active in my colon/rectum, and how does that affect the healing of my fistulas?
  3. 3.Should we check my anti-TNF (Infliximab/Adalimumab) drug levels to see if the dose needs to be optimized?
  4. 4.How do you and my gastroenterologist coordinate my surgical and medical care?
  5. 5.Am I a candidate for stem cell therapy (darvadstrocel) or other regenerative options if my current biologics aren't enough?
  6. 6.What is the goal for my seton—is it long-term drainage or a bridge to a closure procedure?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    The Role of Diet in Pediatric Inflammatory Bowel Disease.

    Albenberg L

    Gastroenterology clinics of North America 2023; (52(3)):565-577 doi:10.1016/j.gtc.2023.05.011.

    PMID: 37543400
  2. 2

    Pathogenesis of Perianal Fistulising Crohn's Disease: Current Knowledge, Gaps in Understanding, and Future Research Directions.

    Cao S, Colonna M, Deepak P

    Journal of Crohn's & colitis 2023; (17(6)):1010-1022 doi:10.1093/ecco-jcc/jjad008.

    PMID: 36655753
  3. 3

    Predictive factors for recurrence of high transsphincteric anal fistula after placement of seton.

    Emile SH, Elfeki H, Thabet W, et al.

    The Journal of surgical research 2017; (213()):261-268 doi:10.1016/j.jss.2017.02.053.

    PMID: 28601324
  4. 4

    MRI of Recurrent Fistula-in-Ano: Is it Different from Treatment-Naïve Fistula-in-Ano and How Does it Correlate with Anal Sphincter Morphology?

    Augustine A, Patel PG, Augustine A, et al.

    The Indian journal of radiology & imaging 2023; (33(1)):19-27 doi:10.1055/s-0042-1758202.

    PMID: 36855724
  5. 5

    The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD.

    Geldof J, Iqbal N, Warusavitarne J, Hart A

    Clinics in colon and rectal surgery 2022; (35(1)):21-31 doi:10.1055/s-0041-1740035.

    PMID: 35069027
  6. 6

    A new protocolized treatment strategy optimizing medical and surgical care leads to improved healing of Crohn's perianal fistulas.

    De Gregorio M, Winata LS, Hartley I, et al.

    Journal of Crohn's & colitis 2025; (19(1)) doi:10.1093/ecco-jcc/jjae199.

    PMID: 39756400
  7. 7

    The efficacy of infliximab combined with surgical treatment of fistulizing perianal Crohn's disease: Comparative analysis according to fistula subtypes.

    Park EJ, Song KH, Baik SH, et al.

    Asian journal of surgery 2018; (41(5)):438-447 doi:10.1016/j.asjsur.2017.06.005.

    PMID: 28851611
  8. 8

    Medical Therapy of Perianal Crohn's Disease.

    Klag T, Goetz M, Stange EF, Wehkamp J

    Viszeralmedizin 2015; (31(4)):265-72 doi:10.1159/000434664.

    PMID: 26557835
  9. 9

    Comparative perianal fistula closure rates following autologous adipose tissue-derived stem cell transplantation or treatment with anti-tumor necrosis factor agents after seton placement in patients with Crohn's disease: a retrospective observational study.

    Park MY, Yoon YS, Lee JL, et al.

    Stem cell research & therapy 2021; (12(1)):401 doi:10.1186/s13287-021-02484-6.

    PMID: 34256838
  10. 10

    Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

    Shehab M, Alrashed F, Heron V, et al.

    Inflammatory bowel diseases 2023; (29(3)):367-375 doi:10.1093/ibd/izac103.

    PMID: 35604382
  11. 11

    CRITICAL ANALYSIS OF ANTI-TNF USE IN THE ERA OF NEW BIOLOGICAL AGENTS IN INFLAMMATORY BOWEL DISEASE.

    Lima CCG, Queiroz NSF, Sobrado CW, et al.

    Arquivos de gastroenterologia 2020; (57(3)):323-332 doi:10.1590/S0004-2803.202000000-59.

    PMID: 33027484
  12. 12

    Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis.

    Lee MJ, Parker CE, Taylor SR, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2018; (16(12)):1879-1892 doi:10.1016/j.cgh.2018.01.030.

    PMID: 29374617
  13. 13

    Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.

    Papamichael K, Vande Casteele N, Jeyarajah J, et al.

    The American journal of gastroenterology 2021; (116(5)):1007-1014 doi:10.14309/ajg.0000000000001111.

    PMID: 33929379
  14. 14

    Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease.

    Gu B, Venkatesh K, Williams AJ, et al.

    World journal of gastroenterology 2022; (28(23)):2597-2608 doi:10.3748/wjg.v28.i23.2597.

    PMID: 35949350
  15. 15

    Darvadstrocel: A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn's Disease.

    Scott LJ

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2018; (32(6)):627-634 doi:10.1007/s40259-018-0311-4.

    PMID: 30298387
  16. 16

    Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

    Panés J, García-Olmo D, Van Assche G, et al.

    Lancet (London, England) 2016; (388(10051)):1281-90.

    PMID: 27477896
  17. 17

    A Phase IB/IIA Study of Ex Vivo Expanded Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease.

    Lightner AL, Reese J, Ream J, et al.

    Diseases of the colon and rectum 2023; (66(10)):1359-1372 doi:10.1097/DCR.0000000000002567.

    PMID: 36602511
  18. 18

    Adipose-Derived Stem Cells in the Treatment of Perianal Fistulas in Crohn's Disease: Rationale, Clinical Results and Perspectives.

    Buscail E, Le Cosquer G, Gross F, et al.

    International journal of molecular sciences 2021; (22(18)) doi:10.3390/ijms22189967.

    PMID: 34576129
  19. 19

    Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

    Panés J, García-Olmo D, Van Assche G, et al.

    Gastroenterology 2018; (154(5)):1334-1342.e4 doi:10.1053/j.gastro.2017.12.020.

    PMID: 29277560
  20. 20

    Factors Associated with Fistulizing Crohn's Disease in Children at Diagnosis: A Cross-Sectional Study.

    Lin YF, Truchon A, Djoukam Mbuko B, et al.

    Inflammatory bowel diseases 2026; (32(2)):237-244 doi:10.1093/ibd/izaf220.

    PMID: 40991894
  21. 21

    Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.

    Strik AS, Löwenberg M, Buskens CJ, et al.

    Scandinavian journal of gastroenterology 2019; (54(4)):453-458 doi:10.1080/00365521.2019.1600014.

    PMID: 31032686
  22. 22

    Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.

    Garcia-Olmo D, Gilaberte I, Binek M, et al.

    Diseases of the colon and rectum 2022; (65(5)):713-720 doi:10.1097/DCR.0000000000002325.

    PMID: 34890373
  23. 23

    INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial.

    Panés J, Bouma G, Ferrante M, et al.

    Inflammatory bowel diseases 2022; (28(11)):1737-1745 doi:10.1093/ibd/izab361.

    PMID: 35099555

This page provides educational information about treating anal fistulas in Crohn's disease. It does not replace professional medical advice. Always consult your gastroenterologist and colorectal surgeon for personalized treatment recommendations.

Get notified when new evidence is published on Anal fistula.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.